Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 3/20 | 0.59 |
| ▸ | HTR6 | P50406 | 3/20 | 0.59 |
| ▸ | SCN1A | P35498 | 2/20 | 0.59 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10336594 | 0.88 | NR2E1 (0.69) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL11745913 | 0.84 | NR2E1 (0.64) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL9327600 | 0.84 | CYP1A2 (0.62) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL29437208 | 0.83 | CYP1A2 (0.83) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL1394219 | 0.83 | CYP1A2 (0.83) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL11552294 | 0.83 | NR2E1 (0.66) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| Chloromethane SCHEMBL11748462 | 0.82 | NR2E1 (0.61) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| Iodomethane SCHEMBL11745775 | 0.82 | NR2E1 (0.61) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL12932618 | 0.82 | NR2E1 (0.60) | NR2E1CYP1A2KDM4EMEN1CYP2C19 | |
| SCHEMBL12932609 | 0.81 | KDM4E (0.64) | CYP1A2KDM4EMEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | VCAM1, VAPB, VAPA | NR2E1 2969/4885CYP1A2 4287/4885KDM4E 4544/4885 |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | VAPB, VCAM1, VAPA | NR2E1 3006/4885CYP1A2 4294/4885KDM4E 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.